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Abstract
Previous studies have shown that regulation of the epidermal growth factor gene (EGFR) pathway plays a role in glioma
progression. Certain genotypes of the EGFR gene may be related to increased glioblastoma risk, indicating that germ line
EGFR polymorphisms may have implications in carcinogenesis. To examine whether and how variants in the EGFR gene
contribute to glioma susceptibility, we evaluated nine tagging single-nucleotide polymorphisms (tSNPs) of the EGFR gene in
a case–control study from Xi’an city of China (301 cases, 302 controls). EGFR SNP associations analyses were performed
using SPSS 16.0 statistical packages, PLINK software, Haploview software package (version 4.2) and SHEsis software
platform. We identified two susceptibility tSNPs in the EGFR gene that were potentially associated with an increased risk of
glioma (rs730437, p=0.016; OR: 1.32; 95%CI: 1.05–1.66 and rs1468727, p=0.008; OR: 1.31; 95%CI: 1.04–1.65). However, after
a strict Bonferroni correction analysis was applied, the significance level of the association between EGFR tSNPs and risk of
glioma was attenuated. We observed a protective effect of haplotype ‘‘AATT’’ of the EGFR gene, which was associated with a
29% reduction in the risk of developing glioma, while haplotype ‘‘CGTC’’ increased the risk of developing glioma by 36%.
Our results, combined with previous studies, suggested an association between the EGFR gene and glioma development.
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Introduction
According to the classification by the World Health Organiza-
tion (WHO), glioma encompasses all tumors that are thought to be
of glial cell origin, including Astrocytic tumors [Astrocytoma
grades I, II (Astrocytoma), III (Anaplastic astrocytoma), and IV
(Glioblastoma or GBM)], Oligodendrogliomas, Ependymomas,
and Mixed gliomas (Central Brain Tumor Registry of the United
States). Gliomas are common tumors and account for almost 80%
of primary malignant brain tumors, usually resulting in poor
survival compared to other types of brain tumors.
Current evidence suggests that inherited risks play a role in
glioma susceptibility, as with other cancers. A majority of the
inherited risk is due to the co-inheritance of multiple low-risk
variants, some of which are commonly seen gene variants and
hence can be identified through association studies [1]. The
epidemiology of glioma has focused on identifying factors that can
be modified to prevent this disease [2–4]. Recent research has
focused on identifying germ line polymorphisms associated with
the risk of glioma and defining molecular markers to classify glial
tumors in more homogenous groups [2–4].
The epidermal growth factor receptor (EGFR) regulates
important cellular processes and is implicated in human tumors.
Several previous studies have assessed single nucleotide polymor-
phisms (SNPs) in the EGFR gene for the association with the risk of
cancers, such as lung cancer [5,6], breast cancer [7], prostate
cancer [8], and esophageal cancer [9]. Somatic alterations of the
EGFR gene are common in glioma and influence several
mechanisms of malignant transformation [10]. Previous studies
have shown that regulation of the EGFR pathway plays an
important role in glioma progression [11], and certain EGFR
genotypes may be related to glioblastoma risk, indicating that
germline EGFR polymorphisms may have important implications
in carcinogenesis of glioma [12].
In addition, it is possible that haplotypes and locus–locus
interactions within the EGFR gene may be correlated with the
development of glioma. To investigate potential relationships
between EGFR SNP polymorphisms, haplotypes, locus–locus
interactions, and their role in the etiology of gliomas, we
performed a comprehensive association analysis in a case–control
study in the Han Chinese population. Our study indicated
important evidence for the association between EGFR gene
polymorphisms and the risk of glioma.
Results
A total of 301 cases (157 male, 144 female; median age at
diagnosis 41.5 yrs) and 302 controls (155 male, 147 female;
median age 42.3 yrs) were included in the current study. Basic
characteristics of the cases and controls were listed in Table 1
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multiplexed SNP MassEXTEND assay was designed with the
Sequenom MassARRAY Assay Design 3.0 Software. Nine SNPs
in the EGFR gene in glioma patients and the control group were
genotyped (raw genotype data are listed in Table S1 and Table
S2). The average tSNPs call rate was 98.5% in cases and controls.
All of the tested tSNPs are in Hardy–Weinberg equilibrium
(HWE) in the control population of this study (Table 3). We
compared the differences in frequency distributions of alleles
between cases and controls by x
2 test and found two significant
tSNPs in the EGFR gene at a 5% level (rs1468727, p=0.008, odds
ratio [OR]: 1.31, 95% confidence interval [CI]: 1.04–1.65 and
rs730437, p=0.016, OR: 1.32, 95%CI: 1.05–1.66). After a strict
Bonferroni correction analysis was applied, we found no associ-
ation between EGFR tSNPs and risk of glioma (Table 3). We
further analyzed the allele frequency differentiation of rs730437
and rs1468727 between diverse groups of cases with varying
aggressive grades and found no association between tumor
aggressiveness and presence of the risk allele (Table S3).
Association results between EGFR tSNP genotypes and the risk
of glioma were listed in Table 4. We identified two significant SNP
genotypes associated with the risk of glioma, one was genotype
‘‘CC’’ of rs1468727 (OR, 1.78; 95% CI, 1.11–2.84; p=0.016) and
the other was genotype ‘‘CC’’ of rs730437 (OR, 1.74; 95% CI,
1.07–2.83; p=0.024).
We assumed that the minor allele of each tSNP was a risk allele
compared to the wild type allele. Minor allele frequency (MAF) in
cases and controls were listed in Table 5. Further model
association analyses were performed by logistic tests. The
rs730437 was observed to be associated with glioma risk by both
recessive model analyses (OR, 1.68; 95% CI, 1.04–2.69; p=0.032)
and additive model analyses (OR, 1.35; 95% CI, 1.05–1. 72;
p=0.019). We also observed another susceptibility SNP,
rs1468727, by recessive model analyses (OR, 1.88; 95% CI,
1.22–2.89; p=0.004) and additive model analyses (OR, 1.37; 95%
CI, 1. 07–1.76; p=0.012).
Three blocks were detected in studied EGFR SNPs by haplotype
analyses (Figure 1). The global result for Block 1 (rs4947492 and
rs12718945) was: total case=594, total control=596, global
x
2=0.106 while df=1, Fisher’s p value=0.744, and Pearson’s p
value=0.744. The global result for Block 2 (rs730437,
rs11506105, rs3752651, and rs1468727) was: total case=582,
total control=559, global x
2=6.584 while df=2, Fisher’s p
value=0.037, and Pearson’s p value=0.037. The global result for
Block 3 (rs845552 and rs9642393) was: total case=578, total
control=572, global x
2=2.79 while df=1, Fisher’s p val-
ue=0.095, and Pearson’s p value=0.095. The global result was:
total case=545, total control=517, global x
2=18.814 while
df=6, Fisher’s p value=0.005, and Pearson’s p value=0.005
(frequency ,0.03 in both the control and case was dropped.).
The results of the association between the EGFR haplotype and
the risk of glioma were listed in Table 6. Haplotype ‘‘CGTC’’ in
Block 2 was found to be associated with the risk of glioma (OR,
1.321; 95% CI, 1.033–1.688; Fisher’s p=0.026; Pearson’s
p=0.026). In Block 2, we also found a protective haplotype
‘‘AATT’’ associated with the risk of glioma (OR, 0.732; 95% CI,
0.576–0.929; Fisher’s p=0.01; Pearson’s p=0.01). Global haplo-
type association analyses showed that haplotype
‘‘TGTAATTGC’’ was associated with an increased risk of glioma
at a 1% level (OR, 0.286; 95% CI, 0.135–0.609; Fisher’s
p=0.001; Pearson’s p=0.001).
Discussion
In this case–control study in a Han Chinese population, we
identified for the first time rs1468727 and rs730437 in the EGFR
gene associated with an increased risk of glioma. A protective
effect was also observed for the haplotype ‘‘AATT’’ of the EGFR
gene that was associated with a 29% reduction in the risk of
developing glioma. Additionally, we also observed a strong effect
of the ‘‘CGTC’’ haplotype, which increased the risk of developing
glioma by 36%.
Our study adopted a genotype and haplotype based approach.
To the best of our knowledge, this study was the first haplotype-
based study that described the association between tSNPs in the
EGFR gene and glioma risk in a Chinese population. Previous
studies focused only on one or two variants in the EGFR gene,
which might not sufficiently capture the effect of susceptibility loci
in Chinese glioma patients. A haplotype-based association
approach is an increasingly accepted approach for genetic
association studies [13]. Using this approach, we provided strong
support that EFGR gene variations contributed to the susceptibility
to glioma.
It is important to note two SNPs (rs1468727 and rs730437) and
their relationship with glioma risk in this study. We found that
genotype ‘‘CC’’ of rs1468727 in intron 13 of the EGFR gene was
associated with the risk of glioma in Chinese patients. Interest-
ingly, genotype ‘‘TT’’ of rs1468727 was found to be associated
with a decreased risk of glioma in a previous study in a European
population (OR, 0.61; 95% CI, 0.40–0.93; p=0.017) [12]. These
results supported our findings that rs1468727 was a susceptibility
loci and the genotype ‘‘CC’’ of this locus was a risk genotype for
glioma. Another SNP, rs730437, located in intron 4 of the EGFR
gene was identified in both studies. In our study, the genotype
‘‘CC’’ of rs730437 was identified as the risk genotype with
frequencies of 0.43 in glioma patients and 0.36 in controls.
However, in the European population, the risk genotype was
‘‘AA’’ (OR, 1.32; 95% CI, 1.03–1.68; p=0.032), with frequencies
of 0.27 in glioma patients and 0.23 in controls [12]. Together,
these findings indicate that ethnic differences among the EGFR
gene variants may affect the development of glioma in diverse
populations. Furthermore, tSNPs rs1468727 and rs730437 may
have a tight linkage with other functional SNPs. Therefore, the
Table 1. Basic characteristics of case and control patients.
Cases (n=301)
Controls
(n=302)
P value
from x
2
No. % No. %
Sex 0.837
Male 157 52.2 155 51.3
Female 144 47.8 147 48.7
Age 0.063
.=50 117 38.9 140 46.4
,50 184 61.1 162 53.6
Median age 41.5 42.3
Histologic type
Astrocytoma 173 57.5
Ependymoma 20 6.6
Glioblastoma 42 14.0
Oligodendroglioma 9 3.0
others 57 18.9
doi:10.1371/journal.pone.0037531.t001
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the EGFR gene is of great interest and warrants further
investigation.
Haplotype analysis suggested that glioma risk was substantially
elevated among individuals with specific haplotypes. Block 2
included four SNPs, one in intron 4, one in the intron/exon
boundary, and two others in intron 13. ‘‘AATT’’ was a protective
haplotype (OR, 0.732), while ‘‘CGTC’’ was a risk haplotype (OR,
1.321). Global haplotype association analyses showed that
haplotype ‘‘TGTAATTGC’’ was associated with the risk of
glioma at a 1% level (OR, 0.286; p=0.001), indicating the
complexity of this gene in the development of glioma.
Some limitations were inherent in this case–control study and
must be noted. The sample size (301 glioma patients and 302
control subjects) was not relatively large among glioma association
studies published to date [2–4]. Glioma patients were not sub-
grouped by age or gender, and gender-specific significant variants
were not tested. We selected tSNPs with MAF higher than 5% in
HapMap Asian populations to affirm the statistical power was
large enough for analyzing data. We performed Bonferroni
correction in our statistical analysis and found no statistical
significant associations between EGFR SNPs and glioma risk. This
may be due to the relatively small sample size, the selection criteria
of EGFR SNPs (MAF .5%), and the weakness of Bonferroni
correction itself. Adjustments for multiple tests, such as Bonferroni
correction analysis, are required for medical association studies,
but also create more problems than they solve [14]. The main
weakness of Bonferroni correction is that the interpretation of a
finding depends on the number of other tests performed. True
important differences may be deemed non-significant since the
likelihood of type II errors are also increased [14]. However,
Bonferroni corrections are considered acceptable when perform-
ing associations without pre-established hypotheses [14]. Another
potential concern was population admixture, which is a known
confounding factor for association analysis and can caused inflated
type-I errors (false positive). In this study, glioma patients and
controls were used in the same hospital to avoid selection bias.
However, this bias was unlikely to be of significance because the
patient groups did not differ in the distributions of demographic
variables and genotype frequencies. We limited all subjects’
ethnicity to Han Chinese, and a living area to Xi’an City and its
surrounding area, thus there was no substantial population
admixture in our study populations.
Our findings in this study provided new evidence for the
association between SNPs and haplotypes of the EGFR gene and
the risk of glioma. The EGFR gene is highly variable, and both
EGFR gene amplification and mutation have been frequently
observed in glioblastoma tumors [15]. EGFR signaling is initiated
by ligand binding to the extracellular ligand-binding domain,
which initiates receptor homo-/hetero-dimerization and auto-
Table 2. PCR primers.
SNP_ID 1st-PCR primer sequences 2nd-PCR primer sequences UEP sequences
rs730437 ACGTTGGATGAGGGAACCAGGCGCAGGTCA ACGTTGGATGAGTGTGAGCTTGCGTCTCAG CAGTGCTGGCCTGAG
rs845552 ACGTTGGATGTCCAACTGTGCGCTCTGCCT ACGTTGGATGGCAAGCATGCTTGGTATTCC TGGTATTCCACAACAATCT
rs1468727 ACGTTGGATGCCACAGCTTGGATCCAGAAA ACGTTGGATGGCCTATCAGCTAAAGGATTC ACTTGGTCCTCTTATCCT
rs3752651 ACGTTGGATGACTTCCAGGAAAAGAGATTC ACGTTGGATGGCACAATAGGAAATAAGCAAG ATATGAAATAAGCAAGTATTATTGCC
rs4947492 ACGTTGGATGTCGTGGTTCCTGTTCATCTG ACGTTGGATGACCAGGAAGTGGAGATAGTC AGTGGAGATAGTCACATATTAGCC
rs9642393 ACGTTGGATGATCTGATAGACCCACTGGGC ACGTTGGATGAACGGGACACACGACTGAAC AGGAACAGCGTTCCCAT
rs11506105 ACGTTGGATGGAGCAAAGGTTCCCTGTGAG ACGTTGGATGGAAAAAGTCTGCAAGTGCTC TCCCCAGTCTGCAAGTGCTCTGCGAC
rs12718945 ACGTTGGATGTAGTTTTCTCAATCCCATG ACGTTGGATGTGTTTCAAGTTGGGAGAAGG GGAGAAGGAGATTATTTAATACTAAAA
rs17172432 ACGTTGGATGTTTCCTCATGGGACACATGG ACGTTGGATGGGAATTTACTATCAAATCTC CAATTTACTATCAAATCTCAGTTGTTA
UEP: Unextended mini-sequencing primer.
doi:10.1371/journal.pone.0037531.t002
Table 3. Examined tSNPs examined in the EGFR gene.
SNP_ID Location Position (Genome build 36.3) HWE p value p value from x
2 p value adj.* OR (95%CI)
rs11506105 7p11.2 55187671(boundary) 0.909 0.053 0.477 1.23(0.97–1.56)
rs12718945 7p11.2 55160457(Intron 1) 0.904 0.777 1 1.04(0.82–1.32)
rs1468727 7p11.2 55197599(Intron 13) 0.757 0.008 0.072 1.31(1.04–1.65)
rs17172432 7p11.2 55108811 (Intron 1) 0.926 0.563 1 0.88(0.61–1.28)
rs3752651 7p11.2 55197037(Intron 13) 0.925 0.232 1 1.11(0.73–1.69)
rs4947492 7p11.2 55155486(Intron 1) 0.882 0.723 1 1.04(0.82–1.32)
rs730437 7p11.2 55182512(Intron 4) 0.960 0.016 0.144 1.32(1.05–1.66)
rs845552 7p11.2 55213001(Intron 19) 0.643 0.105 0.945 1.24(0.98–1.56)
rs9642393 7p11.2 55213141(Intron 19) 0.979 0.115 1 1.2(0.95–1.51)
Note:
*p value was adjusted by Bonferroni corrections.
doi:10.1371/journal.pone.0037531.t003
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receptor activation. The EGFR gene was identified to be
instrumental in glioma formation by EGFR transgenic rats (or
mice) that developed cerebellar glioma [16–17]. In a previous
study, a polymorphism in the 59-untranslated region of the
epidermal growth factor (EGF) gene, a natural ligand of the EGFR,
was identified to play an important role in the pathogenesis of
malignant gliomas [18]. They found that patients with the ‘‘GA’’
or ‘‘GG’’ genotype had higher EGF levels, irrespective of the
EGFR status, were more likely to recur after surgery, and had a
statistically significant shorter overall progression-free survival
than patients with the ‘‘AA’’ genotype. Their findings, combined
with our results, indicate that EGFR pathways may play a key role
in the development of glioma.
Table 4. Association between EGFR tSNP genotypes and the
risk of glioma.
SNP_ID Genotype No. (frequency) OR (95% CI) p value
Case Control
rs11506105 GG 50(16.9) 37(12.5) 1.56(0.94–2.56) 0.081
AG 140(47.3) 137(46.3) 1.18(0.83–1.67) 0.365
AA 106(35.8) 122(41.2) 1(referent) -
rs12718945 TT 36(12.1) 35(11.7) 1.07(0.63–1.81) 0.801
GT 138(46.3) 135(45.2) 1.06(0.76–1.5) 0.725
GG 124(41.6) 129(43.1) 1(referent) -
rs1468727 CC 77(25.8) 50(17.2) 1.78(1.11–2.84) 0.016
TC 143(48) 150(51.7) 1.1(0.75–1.61) 0.623
TT 78(26.2) 90(31) 1(referent) -
rs17172432 CC 2(0.7) 4(1.3) 0.48(0.09–2.67) 0.659
CT 54(17.9) 56(18.9) 0.93(0.62–1.41) 0.742
TT 245(81.4) 237(79.8) 1(referent) -
rs3752651 CC 2(0.7) 1(0.3) 2.02(0.18–22.37) 0.997
CT 46(15.3) 43(14.4) 1.08(0.69–1.69) 0.743
TT 252(84) 254(85.2) 1(referent) -
rs4947492 GG 37(12.3) 36(12) 1.07(0.64–1.8) 0.800
GA 141(46.8) 137(45.5) 1.07(0.76–1.51) 0.694
AA 123(40.9) 128(42.5) 1(referent) -
rs730437 CC 56(18.6) 40(13.3) 1.74(1.07–2.83) 0.024
CA 147(48.8) 139(46.2) 1.32(0.93–1.87) 0.126
AA 98(32.6) 122(40.5) 1(referent) -
rs845552 AA 57(19.1) 43(14.8) 1.5(0.93–2.4) 0.094
GA 132(44.3) 125(43) 1.19(0.84–1.7) 0.333
GG 109(36.6) 123(42.3) 1(referent) -
rs9642393 TT 57(19.5) 43(14.5) 1.48(0.92–2.39) 0.106
CT 135(46.1) 140(47.3) 1.08(0.75–1.54) 0.677
CC 101(34.5) 113(38.2) 1(referent) -
OR: odd ratio; CI: confidence interval.
doi:10.1371/journal.pone.0037531.t004
Table 5. Association between EGFR tSNPs and the risk of glioma based on logistic tests and their heterozygote and homozygote
odds ratios, per allele odds ratios and confidence intervals.
SNP No.
Minor
Allele
MAF
Case
MAF
Control Dominant Model Recessive Model Additive Model
OR 95% CI p OR 95% CI p OR 95% CI p
rs11506105 G 0.41 0.36 1.25 0.88 1.78 0.218 1.58 0.97 2.58 0.069 1.26 0.98 1.62 0.071
rs12718945 T 0.35 0.34 1.03 0.73 1.45 0.881 1.08 0.64 1.83 0.781 1.03 0.80 1.33 0.807
rs1468727 C 0.50 0.43 1.29 0.88 1.89 0.190 1.88 1.22 2.89 0.004 1.37 1.07 1.76 0.012
rs17172432 C 0.10 0.11 0.92 0.60 1.42 0.702 0.61 0.11 3.38 0.571 0.91 0.61 1.35 0.624
rs3752651 C 0.08 0.08 1.09 0.67 1.75 0.739 4.52 0.38 53.81 0.233 1.14 0.72 1.79 0.579
rs4947492 G 0.36 0.35 1.02 0.72 1.44 0.917 1.11 0.66 1.87 0.701 1.04 0.80 1.33 0.793
rs730437 C 0.43 0.36 1.38 0.97 1.97 0.077 1.68 1.04 2.69 0.032 1.35 1.05 1.72 0.019
rs845552 A 0.41 0.36 1.34 0.94 1.91 0.105 1.34 0.84 2.12 0.221 1.24 0.97 1.58 0.081
rs9642393 T 0.42 0.38 1.25 0.87 1.79 0.225 1.38 0.87 2.20 0.169 1.22 0.95 1.56 0.119
MAF: minor allele frequency; OR: odd ratio; CI: confidence interval.
doi:10.1371/journal.pone.0037531.t005
Figure 1. Haplotype block map for all the tSNPs of the EGFR
gene. Block 1 includes rs4947492 and rs12718945; Block 2 includes
rs730437, rs11506105, rs3752651 and rs1468727; and Block 3 includes
rs845552 and rs9642393. The LD between two SNPs is standardized D9
(red schemes).
doi:10.1371/journal.pone.0037531.g001
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responsible for malignant progression and phenotype reversion of
gliomas, and has been used as one of the most important
therapeutic targets. However, the mechanism how germline EGFR
variants contribute to gliomagenesis remains unclear. Since EGFR
gene amplifications were observed commonly in glioblastoma
multiform, we hypothesized that certain mutations or haplotypes
rendered the receptor susceptible to EGFR amplification. In future
studies, to uncover the role of the EGFR gene in gliomagenesis,
serum EGFR expression levels between different mutations or
haplotype groups will be compared. We will also investigate the
association between germline EGFR variants and somatic EGFR
mutations, and the relationship between serum EGFR expression
and somatic EGFR expression in the same glioma subjects.
In conclusion, our comprehensive analysis of SNPs in the EGFR
gene suggests that EGFR genotypes and haplotypes are associated
with glioma risk. These findings indicate that germ-line genetic
variants of the EGFR gene play a complex role in the development
of glioma, and that interactions of loci in the EGFR gene may be
more important than a single locus. Our study offers important
insights into the etiology of glioma.
Materials and Methods
Ethics Statement
The use of human tissue and the protocol in this study were
strictly conformed to the principles expressed in the Declaration of
Helsinki and were approved by the Ethical Committee of Xijing
Hospital for approval of research involving human subjects.
Signed informed consent was obtained from each participant.
Study population
In our study population, all analyses were restricted to Han
Chinese. A total of 301 patients with glioma between November
2008 and December 2010 were recruited into an ongoing
molecular epidemiological study at the Department of Neurosur-
gery of the Xijing Hospital affiliated with The Fourth Military
Medical University (FMMU) in Xi’an city, China. All glioma cases
had no previous history of other cancers, or prior chemotherapy or
radiotherapy. There were no age, sex, or disease stage restrictions
for case recruitment. All patients were recently diagnosed and
histologically confirmed to have glioma.
A random sample of 500 healthy unrelated individuals were
recruited between June 2010 and August 2010 from the medical
examination center at Xijing Hospital, for genetic association
research of human complex diseases, such as lung cancer, stomach
cancer, and glioma. All of the chosen subjects were Han Chinese
living in Xi’an city and its surrounding areas. A detailed
recruitment and exclusion criteria were used. Generally, subjects
with chronic diseases and conditions involving vital organs (heart,
lung, liver, kidney, and brain) and severe endocrinological,
metabolic, and nutritional diseases were excluded from this study.
The purpose of the above exclusion procedures was to minimize
the known environmental and therapeutic factors that influence
the variation of human complex diseases. A total of 302 unrelated
healthy subjects were recruited as controls in this study.
Demographic and clinical data
Demographic and personal data were collected through an in-
person interview using a standardized epidemiological question-
naire, including age, sex, ethnicity, residential region, smoking
status, alcohol use, education status, and family history of cancer.
For patients, detailed clinical information was collected through a
medical chart review or consultation with treating physicians.
Plasma carcinoembryonic antigen and alpha-fetoprotein were
tested in control subjects to make sure they did not have any
cancers.
SNP selection and genotyping
Candidate tSNPs in the EGFR gene were selected from
previously published polymorphisms associated with glioma [12].
Validated tSNPs were selected with a MAF .5% in the HapMap
Asian population. A total of 9 tSNPs in the EGFR gene were
selected for further genotyping. Genomic DNA was extracted from
whole blood using the phenol-chloroform extraction method [19].
DNA concentration was measured by spectrometry (DU530 UV/
VIS spectrophotometer, Beckman Instruments, Fullerton, CA,
USA). A multiplexed SNP MassEXTEND assay was designed
Table 6. EGFR haplotype frequencies and the association with the risk of glioma in case and control patients.
Block Haplotype freq(case) freq(control) x
2 Fisher’s p Pearson’s p OR [95%CI]
1 A G 0.645 0.653 0.106 0.744 0.744 0.961 [0.757,1.221]
G T 0.352 0.342 0.106 0.744 0.744 1.041 [0.819,1.322]
2 A A C C 0.084 0.073 0.514 0.474 0.474 1.171 [0.76,1.804]
A A T T 0.471 0.546 6.571 0.01 0.01 0.732 [0.576,0.929]
C G T C 0.394 0.333 4.945 0.026 0.026 1.321 [1.033,1.688]
3 A T 0.412 0.362 2.79 0.095 0.095 1.226 [0.965,1.556]
G C 0.578 0.622 2.79 0.095 0.095 0.816 [0.643,1.036]
Total C A G A A T T G C 0.04 0.048 0.515 0.473 0.473 0.808 [0.452,1.447]
T A G A A C C G C 0.046 0.028 2.359 0.125 0.125 1.661 [0.864,3.193]
T A G A A T T G C 0.395 0.421 1.669 0.196 0.196 0.843 [0.65,1.093]
T A G C G T C A T 0.086 0.063 1.831 0.176 0.176 1.374 [0.866,2.18]
T G T A A T T G C 0.016 0.053 11.841 0.001 0.001 0.286 [0.135,0.609]
T G T C G T C A T 0.229 0.188 2.239 0.135 0.135 1.258 [0.931,1.7]
T G T C G T C G C 0.036 0.027 0.530 0.467 0.467 1.29 [0.649,2.564]
OR: odd ratio; CI: confidence interval.
doi:10.1371/journal.pone.0037531.t006
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SNP genotyping was performed using the Sequenom MassAR-
RAY RS1000 with a standard protocol recommended by the
manufacturer [20]. Data management and analyses were
performed using the Sequenom Typer 4.0 software as previously
described [20–21].
Statistical analysis
Statistical analyses were performed using Microsoft Excel and
SPSS 16.0 statistical packages (SPSS, Chicago, IL). All p values in
this study were two-sided. A p#0.05 was considered the threshold
for statistical significance. Genotypic frequencies in control
subjects for each SNP were tested for departure from HWE using
an exact test. Allele frequencies and genotype frequencies for each
SNP of glioma patients and control subjects were compared using
the x
2 test [19,22]. ORs and 95% CIs were calculated by
unconditional logistic regression analyses adjusted for age and sex
[23]. We did not divide subjects into subgroups because of the
limited sample size. The possibility of sex differences as a source of
population sub-structure was evaluated by a genotype test for each
SNP in male and female controls, and the number of significant
results at the 5% level was compared with the number expected by
the x
2 test. We did not detect population stratification because all
participants’ ethnicity was Han Chinese.
The three genetic models (dominant, recessive and additive)
were applied by PLINK software (http://pngu.mgh.harvard.edu/
purcell/plink/) to assess the association of single tSNPs with the
risk of glioma. ORs and 95% CIs were calculated by uncondi-
tional logistic regression analyses adjusted for age and sex [23,24].
We used the Haploview software package (version 4.2) and
SHEsis software platform (http://www.nhgg.org/analysis/) for
analyses of linkage disequilibrium, haplotype construction, and
genetic association at polymorphism loci [25,26].
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